Skip to main navigation Skip to search Skip to main content

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Compensated Cirrhosis

Project: Research

Project Details

StatusFinished
Effective start/end date03/21/13 → 03/20/21

Funding

  • Gilead Sciences Incorporated: $318,613.00